Federal Circuit Finds Written Description Support for Narrow Claim Range via Disclosure of Broader Ranges, Vacates PTAB Decision

March 15, 2024

Reading Time : 3 min

The Federal Circuit recently vacated a PTAB decision that claims of an “e-cigarette” patent were unpatentable for lack of written description under 35 U.S.C. § 112. The question on appeal was whether a claimed range was adequately supported by the disclosure of broader ranges. In this case, the answer was “yes.”

The patent-at-issue—RAI Strategic Holdings, Inc.’s U.S. Patent No. 10,492,542—generally relates to “electrically powered smoking articles,” or “e-cigarettes.”  In 2020, Philip Morris Products S.A. sought post grant review of the ’542 Patent, asserting (among other grounds) that dependent claims 10 and 27 were invalid for lack of written description. Those claims recited, in relevant part, a “heating member” with “a length of about 75% to about 85% of a length of [a] disposable aerosol forming substance.”

At the PTAB, Philip Morris argued that the claimed range of “about 75% to about 85%” lacked written description support because the specification disclosed only ranges of 75–125%, 80–120%, 85–115% and 90–110%. According to Philip Morris and its expert, those disclosures did not support the claimed range because (1) they were all “substantially narrower” than the claimed range, (2) none of them recited “an upper limit of 85%” as claimed and (3) they all “centered on” 100%, unlike the claim, which centered on 80%. RAI countered that the disclosed ranges of 75–125% and 85–115% together supported the claim because they expressly include “both ends of the claim range,” i.e., 75% and 85%. Nonetheless, the PTAB agreed with Philip Morris and found the claims unpatentable. RAI appealed.

On appeal, the Federal Circuit vacated the PTAB’s decision, concluding that the facts more closely aligned with decisions finding written description support for a claim range. In re Wertheim, for example, held that the disclosure of coffee grounds with “25% to 60%” solid coffee extract supported a claim range of “between 35% and 60%.” 541 F.2d 257 (C.C.P.A. 1976). Importantly, the Wertheim court found no evidence that the “broad described range pertain[ed] to a different invention than the narrower (and subsumed) claimed range.” 

Here, the Federal Circuit likewise saw no evidence—including from Philip Morris’s expert—that the disclosed ranges were “different inventions” than the claimed range. That is, “nothing in the specification indicate[d] that changing the length of the heating member changes the invention, whether as to operability, effectiveness, or any other parameter.” Although the specification did not disclose the claimed range, it did expressly disclose both endpoints of the claimed range. Moreover, the “predictability of electro-mechanical inventions” such as e-cigarettes further supported the Federal Circuit’s ruling, as predictable art requires “a lower level of detail” to satisfy written description than unpredictable art.

The Court also grappled with cases that found a lack of written description on somewhat similar facts, most notably Indivior UK Ltd. v. Dr. Reddy’s Laboratories S.A., 18 F. 4th 1323 (Fed. Cir. 2021). The Indivior claims recited a therapeutic film comprising “about 48.2 wt % to about 58.6 wt %” polymers. The specification, meanwhile, disclosed a table with a 48.2 wt % polymer and a 58.6 wt % polymer—the endpoints of the claimed range. However, unlike the present case, in Indivior, there was a “lack of persuasive evidence that a skilled artisan would have understood the application as disclosing an invention with the range between these endpoints.” The Indivior patent also differed in that it involved an unpredictable art and the specification made “inconsistent statements regarding the desired amount of polymer.”

Finally, in coming to its conclusion, the Federal Circuit repeatedly emphasized that written description is assessed on a case-by-case basis and that “broadly articulated rules are particularly inappropriate in this area.” Instead, one must consider the technology at issue, the predictability of the art, the complexity of the claim limitation and the knowledge gained by a person skilled in the art reading the specification. Thus, while the Court relied on prior cases for support and guidance, its ruling was ultimately “based on the unique facts of this case.”

Practice Tip: Although claims directed to ranges that are not explicitly disclosed in the specification may be susceptible to written description attacks, particularly in arts regarded as unpredictable, the RAI case shows that such claims may be adequately supported if the disclosed and claim ranges are not shown to be “different inventions.” Parties asserting and defending against such attacks should focus arguments on the specific facts of the case and, if possible, provide expert testimony that addresses how exactly the claim range is (or is not) a different invention from the ranges disclosed in the patent.

RAI Strategic Holdings, Inc. v. Philip Morris Products S.A., No. 22-1862 (Fed. Cir. Feb. 9, 2024)

Share This Insight

Previous Entries

IP Newsflash

October 1, 2025

In a recent final written decision, the PTAB determined that a reference patent was not prior art, despite the petitioner’s post‑filing attempt to correct its petition. While the petitioner argued that it intended to rely on the patent application’s earlier date of publication, both the corrected petition and the expert declaration continued to reference the issued patent rather than the published application.

...

Read More

IP Newsflash

September 30, 2025

The USPTO Director recently granted a petitioner’s request for rehearing of the decision discretionarily denying institution of inter partes review, ultimately vacating the original decision, and referring the petition to the board for an institution decision.

...

Read More

IP Newsflash

September 25, 2025

In considering claims to a method of reducing cardiovascular events, the Federal Circuit held that the term a “clinically proven effective” amount did not render the claims patentable over the prior art. Specifically, the Federal Circuit held that the “clinically proven effective” amount, whether limiting or not, could not be used to distinguish the prior art because the claims also specified the exact amount of the drugs to be administered in the method. The Federal Circuit also rejected patentee’s evidence of unexpected results because that evidence was tied solely to the “clinically proven effective” limitation.

...

Read More

IP Newsflash

September 24, 2025

The Federal Circuit reversed a district court’s denial of judgment as a matter of law on non-infringement, thereby setting aside a $106 million jury verdict, after holding that prosecution history estoppel barred the patentee from asserting infringement under the doctrine of equivalents.

...

Read More

IP Newsflash

September 17, 2025

A magistrate judge in the District of Delaware issued a Report and Recommendation, that found the sole asserted claim was a “single means” claim and therefore invalid for lack of enablement. In reaching that conclusion, the magistrate judge rejected the patentee’s argument that the preamble of the claim disclosed a second element that satisfied the combination requirement of Section 112, paragraph 6 because the preamble simply recited a descriptor of the very apparatus that was the subject of the means-plus-function limitation in the body of the claim. The district court judge presiding over this case has scheduled a hearing to review the magistrate’s ruling.

...

Read More

IP Newsflash

September 9, 2025

The Federal Circuit has affirmed the PTAB’s determination that a patent challenger did not show the challenged claims were unpatentable for obviousness. The Federal Circuit concluded that substantial evidence, which included expert testimony, showed there was no motivation to combine the references.

...

Read More

IP Newsflash

August 29, 2025

In a recent order addressing four IPR proceedings, the PTAB exercised its inherent authority under 37 C.F.R. § 42.5(a) to sua sponte authorize post-hearing discovery on a potentially dispositive privity issue. The order followed a Director review decision that vacated and remanded earlier IPRs involving the same parties, patent family, and privity issue. 

...

Read More

IP Newsflash

August 29, 2025

The Patent Trial and Appeal Board denied institution of an inter partes review petition in part because it determined that a patent reference was not prior art under the common ownership exception of pre-AIA 35 U.S.C. § 103(c)(1).

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.